A Trial to Assess the Effect of an Intervention Integrating Contingency Management (Financial Incentives) to Enhance Hepatitis C Treatment Uptake Following Dried Blood Spot Hepatitis C RNA Testing Among People With Recent Injecting Drug Use Attending Needle and Syringe Programs

A Pilot Two-arm, Individual-level, Randomised Controlled Trial to Assess the Effect of an Intervention Integrating Contingency Management (Financial Incentives) to Enhance Hepatitis C Treatment Uptake Following Dried Blood Spot Hepatitis C RNA Testing Among People With Recent Injecting Drug Use Attending Needle and Syringe Programs

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04428346

Acronym

AMPLIFY

Enrollment

400

Registered

2020-06-11

Start date

2022-10-31

Completion date

2023-12-31

Last updated

2022-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatitis C, Chronic

Brief summary

A pilot two-arm, individual-level, randomised controlled trial to assess the effect of an intervention integrating contingency management (financial incentives) to enhance hepatitis C treatment uptake following dried blood spot hepatitis C RNA testing among people with recent injecting drug use attending needle and syringe programs: the AMPLIFY study

Interventions

BEHAVIORALIncentive payment

Incentive payment to enhance HCV treatment uptake among people with recent injecting drug use attending needle and syringe programs.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

OTHER

Masking

SINGLE (Investigator)

Masking description

Participants will be randomised with a computerised random number generator (or random number table) with block randomisation to assist with keeping participant balance between study arms with a small sample size.

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

1. Participants have voluntarily signed the informed consent form 2. 18 years of age or older 3. Recent injecting drug use (previous six months)

Exclusion criteria

1\) Inability or unwillingness to provide informed consent

Design outcomes

Primary

Measure	Time frame	Description
The proportion of participants who initiate Hepatitis C Virus treatment within 12 weeks of testing	6 months	Data will be presented in percentages and mean (SD) or median values (interquartile range), as appropriate. Chi square test or Fisher's exact test will be utilised, as appropriate, to examine between group differences.

Secondary

Measure	Time frame	Description
Time to HCV treatment initiation	6 months	—
Time to HCV treatment completion	6 months	—
Feasibility of recruitment through a peer-based referral incentivization scheme	6 months	Recruitment numbers
Participant perceptions and acceptability of being involved in a contingency management study will be assessed by study questionnaire	6 months	—
Feasibility of a contingency management intervention to enhance hepatitis C treatment uptake	6 months	Proportion of participants who enrolled in the study and where assigned treatment who commenced treatment.
Time to visit to confirm viral cure (e.g. sustained virological response, SVR12)	6 months	—

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026